Clostridioides (formerly Clostridium) difficile is responsible for a substantial burden of nosocomial infection. Recurrent C. difficile infection (rCDI) remains a concern due to its high morbidity, mortality, and cost. Despite the updated 2017 IDSA C. difficile treatment guidelines, there remains a lack of well-studied preventive control measures and treatment modalities for rCDI. There are ongoing efforts to develop novel therapies, such as new antibiotics with a lesser impact on gut microbiota and more targeted therapies, such as bacteriotherapy. This mini review highlights key rCDI management updates, preventive measures and ongoing research on novel treatment strategies including bacteriotherapy.

Clostridioides（原梭菌）艰难负责医院感染的主要负担。复发性艰难梭菌感染（rCDI）由于其高发病率，高死亡率和高成本而仍然令人担忧。尽管更新了2017年IDSA艰难梭菌治疗指南，但仍缺乏对rCDI进行充分研究的预防控制措施和治疗方式。正在进行开发新疗法的努力，例如对肠道菌群影响较小的新抗生素，以及诸如细菌疗法等更具针对性的疗法。这份小型回顾重点介绍了rCDI管理的主要更新，预防措施以及对包括细菌疗法在内的新型治疗策略的持续研究。